BACKGROUND: Psychosocial screening has been proposed as a core standard of care in pediatric oncology. However, there has been limited application of this standard thus far. Understanding healthcare provider (HCP) attitudes towards psychosocial screening is an important element towards furthering implementation initiatives of standard screening practices in pediatric oncology. OBJECTIVE: To compare HCP perceptions of the utility of a psychosocial risk summary by discipline (oncologist, nurse, social worker), risk level (Universal, Targeted, Clinical) derived from the Psychosocial Assessment Tool (PAT), and time (shortly after a child's diagnosis [T1] and 6 months later [T2]). METHOD: All participating HCPs (oncologists, nurses, social workers) were asked to rate how useful they found the psychosocial risk summary using a visual analogue scale (VAS). RESULTS: The psychosocial risk summary was perceived as equally useful across providers (oncologists, nurses, social workers) and PAT risk levels at T1. At T2, the psychosocial risk summary was perceived as more useful by oncologists and nurses than social workers, and summaries indicating elevated risk were perceived as more useful than those indicating low risk. Overall, healthcare providers reported greater utility of psychosocial risk summary near diagnosis compared with 6 months later, largely driven by lower utility ratings reported by social workers at T2. CONCLUSION: Understanding perceived utility and factors affecting perceived utility is a key component to designing effective implementation strategies for systematic psychosocial screening. Active engagement of HCPs in the screening process is critical in improving implementation of psychosocial screening throughout pediatric cancer treatment.
BACKGROUND:Psychosocial screening has been proposed as a core standard of care in pediatric oncology. However, there has been limited application of this standard thus far. Understanding healthcare provider (HCP) attitudes towards psychosocial screening is an important element towards furthering implementation initiatives of standard screening practices in pediatric oncology. OBJECTIVE: To compare HCP perceptions of the utility of a psychosocial risk summary by discipline (oncologist, nurse, social worker), risk level (Universal, Targeted, Clinical) derived from the Psychosocial Assessment Tool (PAT), and time (shortly after a child's diagnosis [T1] and 6 months later [T2]). METHOD: All participating HCPs (oncologists, nurses, social workers) were asked to rate how useful they found the psychosocial risk summary using a visual analogue scale (VAS). RESULTS: The psychosocial risk summary was perceived as equally useful across providers (oncologists, nurses, social workers) and PAT risk levels at T1. At T2, the psychosocial risk summary was perceived as more useful by oncologists and nurses than social workers, and summaries indicating elevated risk were perceived as more useful than those indicating low risk. Overall, healthcare providers reported greater utility of psychosocial risk summary near diagnosis compared with 6 months later, largely driven by lower utility ratings reported by social workers at T2. CONCLUSION: Understanding perceived utility and factors affecting perceived utility is a key component to designing effective implementation strategies for systematic psychosocial screening. Active engagement of HCPs in the screening process is critical in improving implementation of psychosocial screening throughout pediatric cancer treatment.
Authors: Maria C McCarthy; Claire E Wakefield; Sharon DeGraves; Madeleine Bowden; Deborah Eyles; Lauren K Williams Journal: J Psychosoc Oncol Date: 2016-07-11
Authors: Lori Wiener; Anne E Kazak; Robert B Noll; Andrea Farkas Patenaude; Mary Jo Kupst Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Barbara Jones; Jennifer Currin-Mcculloch; Wendy Pelletier; Vicki Sardi-Brown; Peter Brown; Lori Wiener Journal: Soc Work Health Care Date: 2018-04
Authors: Anne E Kazak; M Catherine Cant; Merritt M Jensen; Mary McSherry; Mary T Rourke; Wei-Ting Hwang; Melissa A Alderfer; David Beele; Steven Simms; Beverly J Lange Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: M Barrera; K Hancock; A Rokeach; D Cataudella; E Atenafu; D Johnston; A Punnett; P C Nathan; U Bartels; M Silva; M Cassidy; P Jansen; W Shama; C Greenberg Journal: Pediatr Blood Cancer Date: 2013-09-17 Impact factor: 3.167
Authors: Melissa A Alderfer; Ifigenia Mougianis; Lamia P Barakat; David Beele; Susan DiTaranto; Wei-Ting Hwang; Anne T Reilly; Anne E Kazak Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Maru Barrera; Alan Rokeach; Priyanga Yogalingam; Kelly Hancock; Donna L Johnston; Danielle Cataudella; Marilyn Cassidy; Angela S Punnett; Wendy Shama Journal: Cancer Nurs Date: 2016 Jul-Aug Impact factor: 2.592
Authors: Sasja A Schepers; Simone M Sint Nicolaas; Heleen Maurice-Stam; Elisabeth M van Dijk-Lokkart; Esther M M van den Bergh; Nienke de Boer; Chris M Verhaak; Martha A Grootenhuis Journal: Support Care Cancer Date: 2017-05-11 Impact factor: 3.603